Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
British Journal of Haematology · 2026-06 · 208 (6) · 2260-2264
DOI: 10.1111/bjh.70479 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Haematology, online erschienen am 14.04.2026. Verfasst von Sosana Delimpasi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Evangelismos Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Menarini Group.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evangelismos Hospital, Athens, Greece.
- First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
- Norton Cancer Institute, Louisville, Kentucky, USA.
- Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- University Hospital of Wales, Cardiff, UK.
ORCID-Profile: Sosana Delimpasi, Ceri Bygrave
Förderung
- Menarini Group
Zitieren
APA
Delimpasi, S., Špička, I., Butler, J. P., Stevens, D. A., Mesa, M. G., Bygrave, C., Merlo, G. M., la Porte, C., & Dimopoulos, M. A. (2026). Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial. British Journal of Haematology, 208(6), 2260-2264. https://doi.org/10.1111/bjh.70479
Vancouver
Delimpasi S, Špička I, Butler JP, Stevens DA, Mesa MG, Bygrave C, et al. Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial. British Journal of Haematology. 2026;208(6):2260-2264. doi:10.1111/bjh.70479
BibTeX
@article{Delimpasi2026,
author = {Delimpasi, Sosana and Špička, Ivan and Butler, Jason P and Stevens, Don A and Mesa, Mercedes Gironella and Bygrave, Ceri and Merlo, Giovanni Marino and la Porte, Charles and Dimopoulos, Meletios A},
title = {Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {6},
pages = {2260--2264},
doi = {10.1111/bjh.70479}
}
EUVIMED